All patients
Asian type ECOG 0 ECOG 1 PD-L1 < 1% PD-L1 > 1% stage II stage III (locally advanced)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
es-BC - TNBC - NA - all population, atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpassion-031 (all population), 2020 0.69 [0.25; 1.89]
0.69 [0.25 ; 1.89 ] IMpassion-031 (all population), 2020 1 0% 333 NA not evaluable events or deaths (EFS)detailed results IMpassion-031 (all population), 2020 0.76 [0.40; 1.44]
0.76 [0.40 ; 1.44 ] IMpassion-031 (all population), 2020 1 0% 333 NA not evaluable pCR detailed results IMpassion-031 (all population), 2020 1.95 [1.26; 3.01]
1.95 [1.26 ; 3.01 ] IMpassion-031 (all population), 2020 1 0% 333 NA not evaluable AE (any grade)detailed results IMpassion-031 (all population), 2020 0.49 [0.02; 14.69]
0.49 [0.02 ; 14.69 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.10 [0.71; 1.72]
1.10 [0.71 ; 1.72 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable AE leading to death (grade 5)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
1.02 [0.06 ; 16.42 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpassion-031 (all population), 2020 1.18 [0.70; 2.01]
1.18 [0.70 ; 2.01 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable SAE (any grade)detailed results IMpassion-031 (all population), 2020 2.00 [1.20; 3.36]
2.00 [1.20 ; 3.36 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable STRAE (any grade)detailed results IMpassion-031 (all population), 2020 1.58 [0.91; 2.75]
1.58 [0.91 ; 2.75 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable TRAE (any grade)detailed results IMpassion-031 (all population), 2020 0.98 [0.14; 7.05]
0.98 [0.14 ; 7.05 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.15 [0.74; 1.77]
1.15 [0.74 ; 1.77 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Diabetes TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
1.02 [0.06 ; 16.42 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Rash TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.32; 3.23]
1.02 [0.32 ; 3.23 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.21 [0.54; 2.69]
1.21 [0.54 ; 2.69 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.54 [0.25; 9.32]
1.54 [0.25 ; 9.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Back pain AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Constipation AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Cough AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 4.15 [0.46; 37.53]
4.15 [0.46 ; 37.53 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dyspepsia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.14; 7.32]
1.02 [0.14 ; 7.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Epistaxis AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.23 [0.37; 4.11]
1.23 [0.37 ; 4.11 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.25 [0.61; 2.57]
1.25 [0.61 ; 2.57 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Headache AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.84 [0.35; 2.00]
0.84 [0.35 ; 2.00 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.44 [0.62; 9.59]
2.44 [0.62 ; 9.59 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.91 [0.36; 2.30]
0.91 [0.36 ; 2.30 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
1.02 [0.06 ; 16.42 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Lacrimation increased AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.86 [0.76; 4.55]
1.86 [0.76 ; 4.55 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Myalgia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Nausea AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.28 [0.06; 1.38]
0.28 [0.06 ; 1.38 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.10 [0.65; 1.84]
1.10 [0.65 ; 1.84 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Oropharyngeal pain AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Paraesthesia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.40 [0.08; 2.09]
0.40 [0.08 ; 2.09 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.28 [0.34; 4.86]
1.28 [0.34 ; 4.86 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.25 [0.03; 2.26]
0.25 [0.03 ; 2.26 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 4.11 [0.18; 91.86]
4.11 [0.18 ; 91.86 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Rash AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 4.15 [0.46; 37.53]
4.15 [0.46 ; 37.53 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 6.20 [0.31; 124.85]
6.20 [0.31 ; 124.85 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.05 [0.18; 22.82]
2.05 [0.18 ; 22.82 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-31 23:55 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 305
- treatments: 1282